Recommended Dosing for 27-Year-Old Male with Moderate-to-Severe Plaque Psoriasis
For a 27-year-old male with moderate-to-severe plaque psoriasis, the optimal first-line biologic dosing depends on body weight and treatment goals, with secukinumab 300 mg (weeks 0-1-2-3-4, then every 4 weeks) or ixekizumab 160 mg initial dose (then 80 mg at weeks 2-4-6-8-10-12, then every 4 weeks) providing the highest efficacy for rapid and complete skin clearance. 1
Weight-Based Dosing Algorithm
If Patient Weighs ≤100 kg:
- Ustekinumab: 45 mg subcutaneously at weeks 0 and 4, then every 12 weeks 1
- Secukinumab: 300 mg at weeks 0-1-2-3-4, then 300 mg every 4 weeks 1
- Ixekizumab: 160 mg initial dose, then 80 mg at weeks 2-4-6-8-10-12, then 80 mg every 4 weeks 1
- Guselkumab: 100 mg at weeks 0 and 4, then every 8 weeks 1
If Patient Weighs >100 kg:
- Ustekinumab: 90 mg subcutaneously at weeks 0 and 4, then every 12 weeks 1
- Secukinumab: 300 mg at weeks 0-1-2-3-4, then 300 mg every 4 weeks (same as lighter patients) 1
- Ixekizumab: Consider 80 mg every 2 weeks if inadequate response at week 24 with standard dosing 1
Strength of Evidence and Treatment Selection
The 2019 AAD-NPF guidelines provide Grade A recommendations for all these biologics 1. The key differentiators are:
IL-17 Inhibitors (Secukinumab/Ixekizumab):
- Highest efficacy: PASI 90 rates of 79% for secukinumab at week 16 1
- Rapid onset: Visible improvement within 2-4 weeks
- Secukinumab 300 mg is superior to 150 mg (Grade A recommendation) 1
- Critical caveat: Avoid in patients with inflammatory bowel disease history 1
- Recent data shows heavier patients (≥90 kg) may benefit from intensified dosing (every 2 weeks) if not achieving PASI 90 by week 24 2
IL-12/23 Inhibitor (Ustekinumab):
- Weight-based dosing is essential: 90 mg for >100 kg patients achieves 75.7% PASI 75 vs 66.7% with 45 mg 1
- Longest dosing interval: Every 12 weeks after loading
- Preferred if psoriatic arthritis present (Grade A) 1
- Can intensify to every 8 weeks if inadequate response 1
IL-23 Inhibitors (Guselkumab):
- Most convenient: Every 8 weeks maintenance dosing 1
- Durable responses: Maintains efficacy with less frequent dosing
- Not weight-adjusted: 100 mg for all patients
Practical Dosing Considerations
For patients prioritizing rapid clearance: Choose secukinumab 300 mg or ixekizumab. The weekly dosing during induction (weeks 0-4 for secukinumab) provides fastest results 1.
For patients prioritizing convenience: Choose guselkumab (every 8 weeks) or ustekinumab (every 12 weeks) after loading 1.
For patients with psoriatic arthritis: TNF-α inhibitors or ustekinumab are preferred as they have FDA approval for preventing joint destruction 1. IL-17 inhibitors (secukinumab/ixekizumab) are also FDA-approved for PsA but lack the joint destruction prevention label 1.
Common Pitfalls to Avoid
Underdosing heavy patients: The 2020 OPTIMISE study demonstrated that patients ≥90 kg not achieving PASI 90 at week 24 benefit from intensified dosing (every 2 weeks for secukinumab) 2
Using 150 mg secukinumab instead of 300 mg: Multiple RCTs show 300 mg is significantly more effective with equal safety 1
Wrong ustekinumab dose for weight: Patients >100 kg require 90 mg, not 45 mg 1
Premature dose escalation: Wait until week 12-24 to assess full response before adjusting 1
Monitoring and Dose Adjustments
If inadequate response at week 12-24:
- Ustekinumab: Increase frequency to every 8 weeks (Grade A) 1
- Secukinumab: Consider every 2-3 weeks if ≥90 kg 2
- Ixekizumab: Increase to every 2 weeks 1
The necessity of repeating loading doses after treatment interruption depends on disease flaring and whether >3-4 half-lives have passed since the previous dose 1.